No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
TECH240621C80000
- 1.20
- 0.000.00%
15min DelayClose Jun 18 15:59 ET
0.00High0.00Low
1.20Open1.20Pre Close0 Volume3.07K Open Interest80.00Strike Price0.00Turnover129.97%IV8.93%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry1.20Extrinsic Value100Contract SizeAmericanOptions Type0.2668Delta0.0423Gamma62.12Leverage Ratio-0.5779Theta0.0012Rho16.57Eff Leverage0.0197Vega
Intraday
- 5D
- Daily
News
Is There Now An Opportunity In Bio-Techne Corporation (NASDAQ:TECH)?
Today we're going to take a look at the well-established Bio-Techne Corporation (NASDAQ:TECH). The company's stock led the NASDAQGS gainers with a relatively large price hike in the past couple of
BIO-TECHNE TO PRESENT AT UPCOMING INVESTOR CONFERENCES
Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the following...
Express News | Quantum-Si Appoints Former Bio-Techne President and CEO, Chuck Kummeth, to Serve as Independent Chairman of the Board of Directors
Express News | Scaleready Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy (Cgt) Development and Manufacturing
Bio-Techne's (NASDAQ:TECH) Investors Will Be Pleased With Their Notable 69% Return Over the Last Five Years
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than that, you probably want to see it rise more than the market average. But Bio-Techn
BIO-TECHNE TO PRESENT AT THE 2024 LEERINK PARTNERS HEALTHCARE CROSSROADS CONFERENCE
Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the 2024 Leerink...
Comments
$Regulus Therapeutics(RGLS.US$ $Bio-Techne(TECH.US$ Bio-Techne And Regulus Therapeutics Announced Continued Technical And Clinical Collaboration Following Regulus' Topline Results From The Second Cohort Of Phase 1B Multiple Ascending Study Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease
1
Despite Bio-Techne's high P/E ratio, the lower forecast growth potentially overvalues it. Investors may risk a share price decline due to weak earnings outlook, posing a risk for those holding onto shares.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after the previous market closed (gaps range from large to small):
Gap Ups
1. $Prudential(PUK.US$ - up 3.18%
2. $Science Applications International(SAIC.US$ - up 1.29%
3. $ICL Group(ICL.US$ - up 1.01%
4. $Novartis AG(NVS.US$ - up 0.56%
5. $MGM Resorts International(MGM.US$ - up 0.4%
Gap Downs
1. $VF Corp(VFC.US$ - down 3.34%
2. $Advanced Drainage(WMS.US$ - down 0....
Gap Ups
1. $Prudential(PUK.US$ - up 3.18%
2. $Science Applications International(SAIC.US$ - up 1.29%
3. $ICL Group(ICL.US$ - up 1.01%
4. $Novartis AG(NVS.US$ - up 0.56%
5. $MGM Resorts International(MGM.US$ - up 0.4%
Gap Downs
1. $VF Corp(VFC.US$ - down 3.34%
2. $Advanced Drainage(WMS.US$ - down 0....
+17
10
1
1
Read more